Treatment
Pembrolizumab clinical trials
We’re tracking 603 recruiting studies that include Pembrolizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06809140RecruitingPhase 2
Bladder-sparing treatment for muscle-invasive bladder cancer
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Duarte, CaliforniaAges 18 years+ - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
San Diego, CaliforniaAges 18 years+ - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06513624RecruitingPhase 1
ETC-159 plus pembrolizumab for advanced ovarian cancer
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Singapore, SingaporeAges 21–99 - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Tucson, ArizonaAges 18 years+ - NCT06764095RecruitingPhase 4
Drug combo before bladder or ureter surgery for advanced cancer
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Rochester, MinnesotaAges 18 years+ - NCT06771544RecruitingPhase 2
Cyclophosphamide and pembrolizumab for advanced melanoma
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Orange, CaliforniaAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT06731907RecruitingPhase 2
Keytruda with or without chemo for advanced lung cancer
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Lexington, KentuckyAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT06669572RecruitingPhase 2
Lenvatinib and pembrolizumab for advanced anal or rectal cancer
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Phoenix, ArizonaAges 18 years+ - NCT06648057Recruiting
Predictors of response in biliary tract cancer
This trial is looking at how certain markers in your blood or tissue (biomarkers) might predict how well the combination of Lenvatinib and Pembrolizumab works against advanced biliary tract cancer. If you're already scheduled to receive these two drugs, researchers want to learn more from your samples to help future patients.
Seongnam-si, Gyeonggi-doAges 20 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+
Common questions
- Are there clinical trials studying Pembrolizumab?
- Yes. Clin2 currently lists 603 recruiting studies that include Pembrolizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pembrolizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pembrolizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pembrolizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.